

Transmitted herewith is a copy of the "Sequence Listing" (sheets 1/23 through 23/23) in paper form for the above-identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the "Sequence Listing" in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Applicant's Attorney submits the following amendments to comply with 37 C.F.R. §1.825:

In the Specification

Please replace the paragraph at page 16, lines 3 through 6 with the following paragraph:

Figure 33 shows a comparison of the UBX domains of several proteins including FAF1-UBX (SEQ ID NO: 17), L1UB3 (SEQ ID NO: 18), L1UB2 (SEQ ID NO: 19), Sumo (SEQ ID NO: 20), Ubiquitin (SEQ ID NO: 21) and L1UB1 (SEQ ID NO: 22), as well as a consensus sequence of the domains in the various proteins.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i ).

Please insert the attached "Sequence Listing" (sheets 1/23 through 23/23), and comprising SEQ ID NOS: 1-22, into the above-referenced application. *aj*